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Background: Dried blood spots (DBS) improve access to HIV viral load (VL) testing, but yield increased VL
measurements compared to the plasma reference method because of cell-associated viral nucleic acid.
In clinical settings, DBS methods may falsely categorize many patients as failing therapy.
Objectives: Description of a simple method, free virus elution (FVE), to preferentially elute plasma-
associated virus from DBS samples with phosphate-buffered saline, and an initial HIV VL performance
comparison with standard DBS elution methods.
Study design: The mechanism of action of FVE was studied with model DBS samples containing puriﬁed
virus or washed HIV-containing cells, andwith a DNA-speciﬁc HIV PCR. Using clinical samples, VL results
from the new FVE method were compared to results from a dried ﬂuid spot procedure (DFSP) protocol,
which uses a guanidinium-based elution method, using plasma VL as the reference method.
Results: Model system experiments suggest that the method efﬁciently separates virus from cell-
associated HIV, with a wide tolerance for incubation time and temperature. In 196 clinical samples,
FVE reduced VL over-quantiﬁcation from DBS, and improved DBS clinical concordance with plasma from
67% to 95%.
Conclusions: A simple elution in PBS signiﬁcantly reduced the over-quantiﬁcation of HIV VL in DBS.
Additional studies are needed to validate the method in ﬁngerstick-collected specimens and to further
understand the compartmentalization of HIV DNA and RNA in DBS specimens.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
World Health Organization guidelines call for viral load (VL)
monitoring of anti-retroviral therapy, but the collection and trans-
portation of plasma can be challenging in resource-limited settings
[1]. Dried blood spots (DBS) are simple to collect and may be
transported at ambient temperature [2]. However, DBS assays may
over-quantify the VLwhen the plasma VL is below 1000 copies/mL,
a decision point for therapeutic efﬁcacy [1,2]. This is likely due to
the cell-associated HIV RNA and DNA that DBS contain, in addition
to the free virus in the plasma component [2].
2. Objectives
Here, we report a simple method which improved test accu-
racy by efﬁciently eluting free HIV virus from DBS, and provide an
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initial HIV VL performance comparison with standard DBS elution
methods.
3. Study design
Dried blood spots derived from 70L whole blood were spot-
ted on Whatman 903 paper. For the standard Roche COBAS®
AmpliPrep/COBAS® TaqMan® (CAP/CTM) dried ﬂuid spot proce-
dure (DFSP), DBSwere extractedwith a guanidinium-based sample
pre-extraction (SPEX) buffer according to package insert instruc-
tions [3]. For the new free virus elution (FVE) protocol, each
DBS was incubated in 1mL of calcium and magnesium-free phos-
phate buffered saline (PBS, 154mMNaCl, 5.6mMNa2HPO4, 1.1mM
KH2PO4, pH 7.4; Corning) in a CAP/CTM S sample tube at room
temperature for >30minwithout shaking. The PBS eluate was then
directly processed in the S tube (without removing the DBS paper)
with thenormalCAP/CTMHIV-1Test v2.0workﬂow,using theDFSP
test deﬁnition ﬁle software [4].
For both FVE and DFSP, the assay software corrects for the
volume difference between a 70L DBS and a 850L plasma
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specimen. FVE titers were further corrected by a factor of 2 (+0.3
log) because FVE is thought to elute only the plasma fraction of
blood,whichaccounts for approximatelyhalf thevolumeof awhole
blood sample.
The FVE mode of action was explored using a model system of
DBS spotted using HIV-negative blood spiked with either puriﬁed
virus 8E5, puriﬁed RNA from 8E5 virus, or washed HIV-containing
cells from the 8E5 cell line [5]. Finally, clinical performance stud-
ies used paired DBS and plasma samples from 196 HIV-infected
patients. VL results from clinical samples processed with the FVE
method were compared to results from the DFSP protocol with
plasma VL measured with the CAP/CTM HIV-1 Test v2.0 as the ref-
erence method. Concordance of the FVE and DSFP methods with
plasma VL for virologic failure was tested with a Fisher exact test
on 2×2 tables.
4. Results
Experiments with spiked samples found that compared to SPEX
(which essentially elutes all cell-free and cell-associated viral
nucleic acid), PBS elution from DBS is approximately 5 times more
selective for cell-free virus than cell-associated HIV nucleic acids.
Using PBS elution, consistent and quantitative elution, deﬁned as
less than a 0.3 log difference among measurements, was observed
with replicate samples over a range of incubation times and tem-
peratures. With incubation times of 0.5, 2 and 12h at 23 ◦C, viral
loads of 3.10, 3.14 and 3.11 log cp/mL VL were measured, respec-
tively. Comparing 0.5h incubations at temperatures of 23, 56 and
70 ◦C, viral loads of 3.38, 3.34 and3.20 log cp/mLVLweremeasured,
respectively.
Eluates from spiked or clinical samples typically showed no
ampliﬁcation with a DNA-speciﬁc assay lacking a reverse tran-
scription step, suggesting that the eluates were primarily RNA.
As PBS does not confer the RNase inactivation that guanidinium
chaotropic buffers provide, sample stability in the presence of high
levels of exogenous RNase A was assessed. The eluate of a clini-
cal HIV-positive DBS sample was resistant to degradation, with a
quantiﬁcation cycle (Cq) of 31.2 without RNase and a Cq value of
32.9 with RNase. The eluate of an HIV-negative DBS sample spiked
with whole virus was also resistant to degradation, with a Cq of
27.4 without RNase and a Cq of 27.1 with RNase. In contrast, the
eluate of an HIV-negative DBS sample spiked with naked viral RNA
showed a Cq of 22.4 without RNase and a Cq of 34.2 with RNase.
A clinical evaluation of themethod used paired DBS and plasma
samples from196HIV patients, both on and off antiretroviral treat-
ment,withplasmaVLs ranging fromundetectable to106 copies/mL.
Using plasma viral load as the reference method, the PBS elution
method reduced VL over-quantiﬁcation from DBS as compared to
the DFSP protocol (Fig. 1). With the standard guanidinium SPEX
extraction of DBS, the concordance between DBS and plasma at
a 1000 cp/mL medical decision point was only 67% due to over-
quantiﬁed viral loads which mistakenly classiﬁed 69% of patients
with plasma viral loads below 1000 cp/mL as treatment failures
(Fig. 2). With PBS elution, the suppressed patients were all cor-
rectly classiﬁed, although 10% of patients with viral loads above
1000 cp/mL were now classiﬁed as treatment successes. Over-
all DBS concordance with plasma signiﬁcantly improved to 95%
(p<0.05, two-tailed z test). PBS elution performed with 90% sen-
sitivity and 100% speciﬁcity, with a PPV of 100% and an NPV of 90%
for virologic failure as deﬁned by plasma viral load.
5. Discussion
A PBS HIV elution of DBS signiﬁcantly reduced the over-
quantiﬁcation of HIV VL in DBS relative to plasma, when compared
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Fig. 1. Viral load measurement from DBS after guanidinium or PBS elution.
Bias plot comparing DBS viral load methods with plasma viral load as the reference
method. Symbols indicate PBS elution () and SPEX (guanidinium) elution (). Com-
pared to plasma, PBS had amean difference of −0.31 log10 copies/mL and a standard
deviation of 0.72 log10 copies/mL, while SPEX had a mean difference of +0.94 log10
copies/mL and a standard deviation of 1.07 log10 copies/mL.
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Fig. 2. Correlation and concordance of viral load measurements from DBS with
plasma.
Symbols indicate PBS elution () and SPEX (guanidinium) elution (). Patients who
potentially would be misclassiﬁed by DBS, using a cut off viral load of 1000 cp/mL
to indicate treatment failure, are indicated by the shaded areas.
to the standard guanidinium extraction protocol. This elution can
be executed in the central laboratory without additional liquid
transfer steps or equipment. Model system experiments suggest
that themethod works by selectively eluting the free virus compo-
nent from the sample while the cell-associated HIV nucleic acids
are retained on the paper. The addition of RNase A to the PBS did
not change virus quantiﬁcation, suggesting that the RNA template
eluted by PBS may be enclosed within protective viral structures.
The FVE protocol improved overall percentage agreement for viro-
logic failure, as deﬁned by a plasma VL>1000 cp/mL, from 67% to
95%, and demonstrated a sensitivity of 90% and a speciﬁcity of 100%
for virologic failure. Adjustment of the VL threshold for virologic
failure for FVE measurements could be used to increase sensitivity
at the cost of decreased speciﬁcity. Additional studies are needed
to validate the method in ﬁeld-collected specimens and to further
understand the compartmentalization of HIV, DNA and RNA in DBS
samples.
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